Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis

New England Journal of Medicine
December 19, 2019 Vol. 381 No. 25


Original Articles
Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis
Dereck R. Tait, M.B. et al
Results of an earlier analysis of a trial of the M72/AS01E candidate vaccine against Mycobacterium tuberculosis showed that in infected adults, the vaccine provided 54.0% protection against active pulmonary tuberculosis disease, without evident safety concerns. We now report the results of the 3-year final analysis of efficacy, safety, and immunogenicity…
…Among adults infected with M. tuberculosis, vaccination with M72/AS01E elicited an immune response and provided protection against progression to pulmonary tuberculosis disease for at least 3 years. (Funded by GlaxoSmithKline Biologicals and Aeras; number, NCT01755598. opens in new tab.)